Broker tips: Shire, ARM Holdings, Transport, Real estate

Panmure Gordon chose to reiterate its 'buy' recommendation on Shire even though the $54bn pursuit by Abbvie is now officially over, highlighting an "opportunity" for investors to pick up shares after recent falls.

Analyst Savvas Neophytou said that the company's rare diseases business still remains "an attractive asset" and that Shire will have "multiple suitors". Allergan and Glaxosmithkline could be potential bidders for Shire's portfolio, he said.

Liberum has kept a 'sell' rating on shares of chip designer ARM Holdings despite a "broadly in-line" third quarter, saying that future prospects are likely to be held back by a slowdown in its end-markets.

While ARM said it remains on track to hit full-year forecasts and painted an upbeat picture for the fourth quarter, Liberum reiterated its negative outlook: "While licensing continues to be strong for the company, we expect royalty growth to disappoint as smartphone and tablet growth continues to slowdown."

Broker Shore Capital welcomed transport group Go-Ahead's latest update but said it was keener on rival Stagecoach.

Shore said it remained a firm supporter of Go-Ahead and its strategy, but it said that it believed there was better value elsewhere in the sector, given the lack of rail franchise news likely in the near term.

Credit Suisse has highlighted an "attractive entry point" for potential investors of Rightmove and Zoopla, downplaying concerns about the threat to the UK estate agent portal industry from newcomer Agents' Mutual.

"We conclude that Agents' Mutual membership is growing, the risks are real and will impact Rightmove and Zoopla 2015 numbers, but that with the stocks down 13% and 17% respectively over the last month the risks are priced in," Credit Suisse said.